<DOC>
	<DOCNO>NCT00903110</DOCNO>
	<brief_summary>The Eu-IGFD descriptive , multicenter , observational , prospective , open-ended , non interventional , post-authorisation surveillance registry . The purpose study collect long-term safety information use recombinant DNA-derived human Insulin-like Growth Factor-1 ( rhIGF-I ) Increlex® replacement therapy treatment child growth failure .</brief_summary>
	<brief_title>European Increlex® ( Mecasermin rDNA Origin Injection ) Growth Forum Database - IGFD Registry</brief_title>
	<detailed_description>Surveillance registry , define post-authorisation observational registry , call Eu-IGFD { European Increlex® ( Mecasermin [ rDNA Origin ] Injection ) Growth Forum Database } intend primarily monitor safety Increlex® replacement therapy child growth failure secondly follow effectiveness treatment . Patients already start Increlex® therapy enter observational registry may include registry data collect retrospectively .</detailed_description>
	<criteria>All subject begin therapy Increlex® previously treat Increlex® participate qualified practitioner Parents legally authorize representative applicable must give sign informed consent registryrelated activity conduct . Assent subject also obtain appropriate Subject currently participate Increlex® clinical trial Subject currently participate clinical trial growth retardation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>